曲美他嗪与阿托伐他汀联合治疗冠心病的临床效果分析

Clinical analysis of trimetazidine combined with atorvastatin in the treatment of coronary heart disease

目的分析曲美他嗪与阿托伐他汀联合治疗冠心病的临床效果。方法回顾性分析我院收治的120例冠心病患者的临床资料,根据不同治疗方式将其分为A组(40例,给予曲美他嗪治疗)、B组(40例,给予阿托伐他汀治疗)以及C组(40例,给予曲美他嗪与阿托伐他汀联合治疗)。对比三组患者的血脂改善及临床症状缓解情况。结果治疗后,A组与B组患者的各血脂指标水平稍优于治疗前,但差异无统计学意义(P>0.05);C组患者治疗后的LDL-C、TG及TC水平降低,HDL-C水平升高,且均优于治疗后的A组与B组(P<0.05)。A、B组患者的心悸、胸部疼痛以及全身乏力缓解率比较,无显著差异(P>0.05);与A、B组相比较,C组患者的心悸、胸部疼痛以及全身乏力缓解率更高(P<0.05)。结论曲美他嗪与阿托伐他汀联合治疗冠心病患者的临床效果十分显著,有利于进一步改善患者的血脂指标水平与临床症状,值得在临床治疗工作中推广运用。

Objective To analyze the clinical effect of trimetazidine combined with atorvastatin in the treatment of coronary heart disease. Methods The clinical data of 120 patients with coronary heart disease who treated in our hospital were retrospectively analyzed. The patients were divided into the group A（40 cases, received trimetazidine treatment）, the group B（40 cases, received atorvastatin treatment） and the group C（40 cases, received trimetazidine combined with atorvastatin treatment） according to different treatment methods. The blood lipids improvement and clinical symptoms situation were compared among the three groups. Results After treatment, the levels of blood lipids in the group A and B were slightly better than those before treatment, but the differences were not statistically significant（P〈0.05）; the levels of LDL-C, TG and TC decreased and the level of HDL-C increased in the group C, and those were better than the group A and group B（P 0.05）. There were no significant differences in the palpitations, chest pain and generalized fatigue remission rate between the group A and group B（P〈0.05）; compared with the group A and group B, the palpitations, chest pain and generalized fatigue remission rate were higher in the group C（P〈0.05）. Conclusion Timetazidine combined with atorvastatin has remarkable effect on coronary heart disease, which is helpful to further improve the blood lipids indexes levels and clinical symptoms, and it is worth to be used in clinical treatment.